Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LENZ LENZ Therapeutics	$29.33 -2.1%	$31.05	$16.53 ▼ $38.93	$854.52M	0.42	357,073 shs	381,899 shs
MLTX MoonLake Immunotherapeutics	$53.32 +0.8%	$47.75	$31.42 ▼ $58.26	$3.39B	1.27	557,249 shs	482,312 shs
PTCT PTC Therapeutics	$52.25 +0.2%	$49.21	$29.01 ▼ $58.38	$4.13B	0.54	1.17 million shs	1.01 million shs
SWTX SpringWorks Therapeutics	$46.99	$46.90	$28.21 ▼ $62.00	$3.54B	0.68	2.66 million shs	N/A

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LENZ LENZ Therapeutics	-2.10%	-6.92%	-9.85%	+12.94%	+22.11%
MLTX MoonLake Immunotherapeutics	+0.76%	-2.11%	+15.00%	+35.81%	+29.17%
PTCT PTC Therapeutics	+0.23%	+17.80%	+7.13%	+44.38%	+62.32%
SWTX SpringWorks Therapeutics	0.00%	0.00%	0.00%	+1.80%	+40.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LENZ LENZ Therapeutics	1.6876 of 5 stars	3.6	0.0	0.0	0.0	3.7	0.8	0.0
MLTX MoonLake Immunotherapeutics	2.7337 of 5 stars	4.4	0.0	0.0	0.0	3.3	2.5	0.0
PTCT PTC Therapeutics	4.4898 of 5 stars	4.3	2.0	0.0	4.4	3.0	0.8	1.3
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LENZ LENZ Therapeutics	3.17	Buy	$49.60	69.11% Upside
MLTX MoonLake Immunotherapeutics	2.78	Moderate Buy	$73.14	37.18% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$69.38	32.79% Upside
SWTX SpringWorks Therapeutics	2.13	Hold	$52.57	11.88% Upside

Current Analyst Ratings Breakdown

Latest LENZ, PTCT, SWTX, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2025	LENZ LENZ Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $49.00
7/31/2025	LENZ LENZ Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
7/29/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$80.00 ➝ $86.00
7/29/2025	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $46.00
7/29/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$68.00 ➝ $84.00
7/29/2025	PTCT PTC Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$71.00 ➝ $80.00
7/29/2025	PTCT PTC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$112.00 ➝ $120.00
7/29/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$74.00 ➝ $78.00
7/28/2025	PTCT PTC Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$40.00 ➝ $50.00
7/28/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $48.00
7/28/2025	MLTX MoonLake Immunotherapeutics	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 8/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LENZ LENZ Therapeutics	$5M	167.31	N/A	N/A	$7.42 per share	3.95
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$7.09 per share	N/A
PTCT PTC Therapeutics	$806.78M	5.13	N/A	N/A	($14.24) per share	-3.67
SWTX SpringWorks Therapeutics	$191.59M	18.48	N/A	N/A	$6.47 per share	7.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LENZ LENZ Therapeutics	-$49.77M	-$1.90	N/A	N/A	N/A	N/A	-25.63%	-24.43%	8/13/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.30	N/A	N/A	N/A	N/A	-30.81%	-28.40%	8/6/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	8.03	N/A	N/A	33.56%	-78.56%	32.11%	8/7/2025 (Estimated)
SWTX SpringWorks Therapeutics	-$258.13M	-$3.41	N/A	N/A	N/A	-115.60%	-51.10%	-43.80%	8/6/2025 (Estimated)

Latest LENZ, PTCT, SWTX, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	LENZ LENZ Therapeutics	-$0.62	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	PTCT PTC Therapeutics	-$1.07	N/A	N/A	N/A	$173.01 million	N/A
8/6/2025	Q2 2025	MLTX MoonLake Immunotherapeutics	-$0.73	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	SWTX SpringWorks Therapeutics	-$0.81	N/A	N/A	N/A	$73.39 million	N/A
7/30/2025	Q2 2025	LENZ LENZ Therapeutics	-$0.58	-$0.53	+$0.05	-$0.53	$5.00 million	$5.00 million
5/12/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.76	-$0.63	+$0.13	-$0.63	N/A	N/A
5/9/2025	Q1 2025	SWTX SpringWorks Therapeutics	-$0.81	-$1.11	-$0.30	-$1.11	$64.19 million	$49.09 million
5/7/2025	Q1 2025	LENZ LENZ Therapeutics	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LENZ LENZ Therapeutics	N/A	20.54	20.54
MLTX MoonLake Immunotherapeutics	0.18	21.11	21.11
PTCT PTC Therapeutics	N/A	3.89	3.85
SWTX SpringWorks Therapeutics	N/A	4.33	4.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LENZ LENZ Therapeutics	54.32%
MLTX MoonLake Immunotherapeutics	93.85%
PTCT PTC Therapeutics	N/A
SWTX SpringWorks Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
LENZ LENZ Therapeutics	6.90%
MLTX MoonLake Immunotherapeutics	12.02%
PTCT PTC Therapeutics	5.50%
SWTX SpringWorks Therapeutics	7.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LENZ LENZ Therapeutics	110	28.52 million	26.55 million	N/A
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.30 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable
SWTX SpringWorks Therapeutics	230	75.35 million	69.45 million	Optionable

LENZ, PTCT, SWTX, and MLTX Headlines

Recent News About These Companies

European Commission Grants Conditional Approval for SpringWorks Therapeutics' EZMEKLY® to Treat Plexiform Neurofibromas in NF1 Patients

July 18, 2025 | quiverquant.comQ

SpringWorks Therapeutics Receives Conditional EU Approval for EZMEKLY® to Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

July 18, 2025 | quiverquant.comQ

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

July 18, 2025 | globenewswire.com

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

July 18, 2025 | globenewswire.com

Principal Financial Group Inc. Trims Stake in SpringWorks Therapeutics (NASDAQ:SWTX)

July 7, 2025 | marketbeat.com

SpringWorks Therapeutics Completes Merger and Delisting

July 1, 2025 | tipranks.com

SpringWorks Therapeutics Inc (SWTX) - Investing.com

June 28, 2025 | investing.com

SpringWorks Therapeutics Nears EU Approval for First Desmoid Tumor Therapy, Nirogacestat

June 24, 2025 | msn.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat as Potential First Treatment for Desmoid Tumors in the EU

June 20, 2025 | quiverquant.comQ

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

June 20, 2025 | globenewswire.com

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

June 3, 2025 | businesswire.com

SpringWorks Therapeutics (SWTX) Surged on Acquisition News

May 27, 2025 | msn.com

SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges

May 26, 2025 | investing.com

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

May 26, 2025 | zacks.com

SpringWorks gets EU endorsement for genetic disorder treatment

May 23, 2025 | msn.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

May 23, 2025 | globenewswire.com

SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates

May 9, 2025 | zacks.com

HC Wainwright & Co. Downgrades SpringWorks Therapeutics (SWTX)

May 1, 2025 | msn.com

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

April 30, 2025 | businesswire.com

Guggenheim Downgrades SpringWorks Therapeutics (SWTX)

April 30, 2025 | msn.com

Wall Street Analysts Believe SpringWorks Therapeutics (SWTX) Could Rally 42.29%: Here's is How to Trade

April 29, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LENZ, PTCT, SWTX, and MLTX Company Descriptions

LENZ Therapeutics NASDAQ:LENZ

$29.33 -0.63 (-2.10%)

Closing price 08/4/2025 04:00 PM Eastern

Extended Trading

$29.53 +0.20 (+0.68%)

As of 08/4/2025 07:22 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

MoonLake Immunotherapeutics NASDAQ:MLTX

$53.32 +0.40 (+0.76%)

Closing price 08/4/2025 04:00 PM Eastern

Extended Trading

$54.48 +1.16 (+2.18%)

As of 08/4/2025 05:19 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

PTC Therapeutics NASDAQ:PTCT

$52.25 +0.12 (+0.23%)

Closing price 08/4/2025 04:00 PM Eastern

Extended Trading

$53.00 +0.76 (+1.44%)

As of 08/4/2025 06:26 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

SpringWorks Therapeutics NASDAQ:SWTX

$46.99 0.00 (0.00%)

As of 07/1/2025

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time